Atovaquone/proguanil
PreclinicalSmall molecule
PfizerAtovaquone/proguanil is one of 5 small molecule programs targeting Plasmodium Falciparum. It is currently in Preclinical.
1
Indications
6
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Plasmodium Falciparum
#DrugCompanyPhaseTrials
1Chloroquine Prophylaxis
RRadboud University Medical Center
Preclinical
Plasmodium Falciparum Challenge
RRadboud University Medical Center
Preclinical
Atovaquone/proguanil
PfizerPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Controlled Human Malaria Infection
RRadboud University Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Plasmodium Falciparum2 trials
Immunization1 trial
Malaria1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atovaquone/proguanil. EMBL-EBI & Wellcome Sanger Institute.
- [4]